<DOC>
	<DOCNO>NCT02014545</DOCNO>
	<brief_summary>This randomize , double blind placebo control study evaluate safety efficacy lucanthone administer adjunct patient receive whole brain radiation therapy ( WBRT ) primary treatment brain metastasis secondary non-small cell lung cancer .</brief_summary>
	<brief_title>Evaluation Lucanthone Whole Brain Radiation Therapy Patients With Brain Metastases From Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Eligible patient trial randomize lucanthone placebo ratio 1:1 . The treatment consist WBRT give dose 30 Gy ten fraction . Lucanthone/placebo give adjunct WBRT day WBRT administer . Tumor assessment do brain MRI . Radiological assessment tumor make periodically throughout study discontinue time tumor progression . Safety evaluate one year study period survival data collect thereafter .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Lucanthone</mesh_term>
	<criteria>The patient give informed consent . The patient willing able abide protocol . The patient age 18 70 ( 19 70 Alabama ) . The patient histologically proven NSCLC radiologically document brain metastasis . Newly diagnose stable systemic disease , systemic therapy . If receive systemic therapy NSCLC , least two week since patient receive systemic therapy . Able withhold systemic therapy duration WBRT therapy . If patient childbearing potential , he/she use acceptable/effective method contraception . The patient 's Karnofsky Score great equal 70 % . Patient diagnosis recurrent brain metastasis . The patient absolute neutrophil count less equal 1.5 X 10 9/L . The patient screen platelet count less 100,000/uL . The patient screen bilirubin great 1.6 mg/dL . The patient screen creatinine great 2.25 mg/dL men 1.8 mg/dL woman . The patient screen ALT/AST great 2.5 time upper limit laboratory reference range . The patient unstable medical condition significant comorbid pathophysiology ( e.g . active infection , poorly control diabetes , unstable angina , severe heart failure ) would interfere his/her participation study . The patient enrol , plan enroll , concurrent treatment protocol another investigational product . The patient receive prior chemotherapy radiation therapy within two week begin WBRT protocol . The patient allergic gadolinium contrast . More 21 day elapse brain MRI document brain metastasis initiation WBRT .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>brain metastasis</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>whole brain radiation therapy</keyword>
	<keyword>lucanthone</keyword>
</DOC>